Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?

Merola, Elettra; Rinke, Anja; Partelli, Stefano; Gress, Thomas M.; Andreasi, Valentina; Kollár, Attila; Perren, Aurel; Christ, Emanuel; Panzuto, Francesco; Pascher, Andreas; Jann, Henning; Arsenic, Ruza; Cremer, Birgit; Kaemmerer, Daniel; Kump, Patrizia; Lipp, Rainer W.; Agaimy, Abbas; Wiedenmann, Bertram; Falconi, Massimo and Pavel, Marianne E. (2020). Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms? Annals of surgical oncology, 27(5), pp. 1348-1355. Springer 10.1245/s10434-019-08049-5

[img] Text
s10434-019-08049-5.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (376kB) | Request a copy

BACKGROUND: While platinum-based chemotherapy represents the standard treatment for advanced grade 3 (G3) neuroendocrine neoplasms (NENs) according to the European Neuroendocrine Tumor Society guidelines, the role of radical-intended surgery in these patients, as well as the use of adjuvant chemotherapy, are still controversial. The aim of the present work is to describe, in a retrospective series of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) G3, the overall survival (OS) rate and risk factors for death after radical surgery. Secondary aims are the description of median recurrence-free survival (RFS) and of the role of adjuvant chemotherapy. PATIENTS AND METHODS: Multicenter analysis of a series of stage I-III GEP-NEN G3 patients receiving radical surgery (R0/R1) with/without adjuvant chemotherapy was performed. RESULTS: Sixty patients from eight neuroendocrine tumor (NET) referral centers, with median follow-up of 23 months (5-187 months) were evaluated. While 28.6% of cases had NET G3, 71.4% had neuroendocrine carcinoma G3 (NEC G3). The 2-year OS rate after radical surgery was 64.5%, with a statistically significant difference in terms of Ki67 threshold (cut-off 55%, P = 0.03) and tumor differentiation (NEC G3 vs. NET G3, P = 0.03). Median RFS after radical surgery was 14 months, and 2-year RFS rate was 44.9%. Use of adjuvant chemotherapy provided no benefit in terms of either OS or RFS in this series. CONCLUSIONS: Surgery with radical intent might represent a valid option for GEP-NEN G3 patients with locoregional disease, especially with Ki67 value ≤ 55%.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Kollár, Attila and Perren, Aurel

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

1068-9265

Publisher:

Springer

Language:

English

Submitter:

Rebeka Gerber

Date Deposited:

03 Dec 2019 12:34

Last Modified:

10 Apr 2020 01:31

Publisher DOI:

10.1245/s10434-019-08049-5

PubMed ID:

31720931

BORIS DOI:

10.7892/boris.135674

URI:

https://boris.unibe.ch/id/eprint/135674

Actions (login required)

Edit item Edit item
Provide Feedback